Tenofovir amibufenamide does not alter lipid levels in patients with chronic hepatitis B

Background and aims

The effect of tenofovir amibufenamide (TMF) on blood lipid profiles in patients with chronic hepatitis B (CHB) remains unclear. This study aimed to explore whether TMF affects blood lipids during 48 weeks in patients with CHB.

Methods

Results

Conclusions

Regardless of baseline blood lipid characteristics, 48 weeks of antiviral treatment with TMF in patients with CHB had no significant lipid-raising effect.

Source:

Xia & He Publishing Inc.

Journal reference: